Earlier this year, CMS rolled back several payer transparency requirements that had been finalized in 2024. The reductions were modest in policy terms, but they had a concrete effect on what payer behavior data is now publicly available. Health equity analyses of prior authorization practices were suspended. Plan-level reporting (as opposed to aggregate contract-level reporting) was deferred. Some smaller payer disclosure requirements were softened or withdrawn.

Most of the trade coverage framed this as a reduction in payer accountability. That framing is not wrong. But there is a second-order effect that is worth understanding because it changes what is valuable in a clearinghouse relationship.

With less public payer behavior data available, the institutional knowledge your clearinghouse holds got more valuable, not less.

What ’Institutional Payer Knowledge’ Actually Means

Every healthcare clearinghouse routes claims, eligibility checks, and ERAs across hundreds of payers, day after day, year after year. In the process, the clearinghouse accumulates structured knowledge about how each payer actually behaves:

• Which modifiers cause denials at specific payers even though they pass generic validation
• Which code combinations a specific payer rejects under medical necessity review
• Which documentation requirements a specific payer enforces strictly versus loosely
• How a specific payer changes its adjudication patterns over time, and how often
• Which prior authorization formatting and clinical documentation patterns get approved first-pass at a specific payer versus which trigger review
• Which payers have updated their edit rules in the past 30, 60, or 90 days, and what changed

This knowledge is not the same as the public payer rule documentation that payers publish (and sometimes do not publish). It is the operational reality of how the payer actually adjudicates, which is often different from how the payer says it adjudicates. The gap between official rules and observed behavior is where preventable denials live.

Why Public Data Is Less Available Now

The 2024 CMS rules had moved the industry toward more public disclosure of payer behavior. The 2025 rollback partially reversed that trajectory. Plan-level reporting, which would have shown payer behavior at a granular level where individual practices could see how their specific contract was being handled, was suspended. Health equity analyses, which would have surfaced denial rate disparities across patient demographics, were deferred.

The aggregate CMS-0057-F data is still public. Payer denial rates at the contract level, appeal overturn rates, and standard turnaround times are still being published annually. But the finer-grained data that would have given practices direct visibility into payer-specific behavior at the local plan level is back behind the curtain.

That gap is exactly where institutional clearinghouse knowledge becomes the substitute. The data that is no longer publicly available is still observable, on a daily basis, in the transaction stream flowing through a clearinghouse that has been routing claims to that payer for years.

Why Longevity in Clearinghouse Operations Matters More Than Ever

A clearinghouse with two decades or more of continuous operation has tracked payer behavior across:

• Every major payer system change
• Every CMS regulatory shift
• Every Medicare Advantage market consolidation
• Every Medicaid managed care expansion
• Every shift in payer adjudication technology, from rules-based engines to AI-driven review

That accumulated track record is structurally hard to replicate. A new entrant clearinghouse, no matter how strong its technology, does not have the institutional memory of how UnitedHealthcare handled modifier 25 on commercial plans in 2020 versus 2023 versus today. That memory is built into the edit rules of a long-tenured clearinghouse. It is not built into a new one.

When public data is plentiful, the institutional knowledge advantage matters but is partially substitutable through public reporting. When public data is reduced, the institutional knowledge becomes harder to substitute. The information moat widens.

What This Means for Practice Decisions

Three implications for practices evaluating clearinghouse relationships in 2026 and beyond:

• Ask about payer-specific edit rule depth. Specifically: how many payer-specific rules are in the scrubbing layer, how frequently are they updated, and how does the vendor source the data that drives those updates? Generic answers usually mean generic rules.
• Evaluate longevity as evidence, not marketing. A clearinghouse that has been routing claims for 5 years cannot know what one that has been routing for 25 knows. The track record is the evidence.
• Ask for examples of recent edit rule changes the vendor caught. A vendor that actively tracks payer behavior should be able to point to specific examples of changes they identified and built into scrubbing in the past 90 days.

How HSC Approaches Institutional Knowledge

Harris Secure Connect has routed healthcare transactions for 26 years across thousands of payer connections. That tenure is the source of an edit-rule depth that is structurally harder to build than to maintain. In an environment where public payer transparency is partial and uneven, that institutional knowledge translates directly into denial prevention at scale.

If you have started to feel like your current clearinghouse is reactive to payer changes rather than ahead of them, that is a signal. Reach out and we can walk through what payer-specific edit depth looks like in practice.

Related Resources

• CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)
• KFF analysis of payer transparency policy
• HHS regulatory dockets

Curious whether your current clearinghouse has the institutional payer knowledge to keep your denial rate flat in an environment of reduced public transparency? Reach out for a no-pressure conversation.